Converge Bio

• ·Converge Bio’s last known valuation is $90.0M (Jan 2026).
• ·It has raised $30.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($25.0M) in Jan 2026.
• ·Notable investors include Bessemer Venture Partners, AWS Startups, TLV Partners, Vintage (Private Equity), AuroraAxis Capital — 6 tracked in total.
• ·1 investment vehicle was formed to buy Converge Bio shares in the last 12 months, reporting $155K sold to 2 investors, per SEC Form D filings.
• ·Converge Bio has filed 1 Form D with the SEC, most recently Apr 2026 ($25.0M sold to 19 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 1 investment vehicle were formed to buy Converge Bio shares, reporting $155K sold to 2 investors. Most recent filing Oct 2025. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of a biotech platform designed to apply generative artificial intelligence to biological data for advancing drug discovery and development. The company's platform offers capabilities for molecule design, antibody engineering, target and biomarker identification, and protein yield optimization, enabling pharmaceutical and biotechnology companies to increase efficiency, accuracy, and consistency across drug development workflows.

Industry

Other Information Technology

Sector

Information Technology

HQ

Wilmington, DE, United States

Founded

2024

Employees

40

Website

converge-bio.com/

Ownership

Privately Held (backing)